Milind Deshpande

Milind Deshpande, PhD, serves as Chairman of the Spero Therapeutics Board of Directors. Milind joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President Research and Development in October 2010. From May 2013 to May 2018, Dr. Deshpande served as President and Chief Executive Officer of Achillion and was on the Board of Directors. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his PhD in Organic Chemistry from Ohio University, following his undergraduate education in India.